EUVIMEDEUVIMED entdecken
Klinische StudieMultizentrische Studie

Real-World Effectiveness and Safety of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: A 16-Week Study in Japan

Teppei Hagino iD, Akihiko Uchiyama, Marina Onda, Keiji Kosaka, Takeshi Araki, Sei-Ichiro Motegi, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda

Dermatitis® · 2026

DOI: 10.1089/derm.2025.0004 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Dermatitis®, 2026. Verfasst von Teppei Hagino und 8 weiteren Autor:innen. Beteiligte Einrichtung: From the, Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Dermatitis, Atopic, Dermatologic Agents. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 55 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Real-world data on the effectiveness and safety of lebrikizumab for atopic dermatitis (AD) are limited.

Objective

To evaluate the real-world effectiveness and safety of lebrikizumab on Japanese patients with AD.

Methods

This two-center study included 126 Japanese patients with moderate-to-severe AD treated with lebrikizumab plus topical corticosteroids for 16 weeks. Eczema area and severity index (EASI), investigator’s global assessment (IGA), peak-pruritus (PP)-numerical rating scale (NRS), sleep quality NRS, AD control tool (ADCT), dermatology life quality index (DLQI), patient-oriented eczema measure (POEM), immunoglobulin E (IgE), thymus and activation-regulated chemokine (TARC), lactate dehydrogenase (LDH), and total eosinophil count (TEC) were assessed during the treatment.

Results

Lebrikizumab reduced all clinical indexes at week 4, which was maintained until week 16. The achievement rates of EASI 50, 75, 90, 100, and IGA 0/1 at week 16 were 83.1%, 57.1%, 27.3%, 11.7%, and 33.3%, respectively. The achievement rates of ≥4-point reduction in PP-NRS, sleep quality NRS, or DLQI, ADCT

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalDermatitis, AtopicDermatologic AgentsAdultFemaleHumansMaleMiddle AgedYoung AdultChemokine CCL17EosinophilsImmunoglobulin EJapanL-Lactate DehydrogenaseQuality of LifeSeverity of Illness IndexTreatment OutcomeAdolescentAntibodies, Monoclonal, Humanized

Substanzen

Antibodies, MonoclonalCCL17 protein, humanChemokine CCL17Dermatologic AgentsImmunoglobulin EL-Lactate DehydrogenaselebrikizumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • From the, Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Inzai, Japan.
  • Department of Dermatology, Gunma University Graduate School of Medicine, Maebashi, Japan.
  • Department of Dermatology, Nippon Medical School, Tokyo, Japan.
  • Fujimoto Dermatology Clinic, Funabashi, Japan.

ORCID-Profile: Teppei Hagino

Zitieren

APA

Hagino, T., Uchiyama, A., Onda, M., Kosaka, K., Araki, T., Motegi, S. I., Saeki, H., Fujimoto, E., & Kanda, N. (2026). Real-World Effectiveness and Safety of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: A 16-Week Study in Japan. Dermatitis®. https://doi.org/10.1089/derm.2025.0004

Vancouver

Hagino T, Uchiyama A, Onda M, Kosaka K, Araki T, Motegi SI, et al. Real-World Effectiveness and Safety of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: A 16-Week Study in Japan. Dermatitis®. 2026. doi:10.1089/derm.2025.0004

BibTeX
@article{Hagino2026,
  author = {Hagino, Teppei and Uchiyama, Akihiko and Onda, Marina and Kosaka, Keiji and Araki, Takeshi and Motegi, Sei-Ichiro and Saeki, Hidehisa and Fujimoto, Eita and Kanda, Naoko},
  title = {Real-World Effectiveness and Safety of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis: A 16-Week Study in Japan},
  journal = {Dermatitis®},
  year = {2026},
  doi = {10.1089/derm.2025.0004}
}
Kostenlos starten →